TeneoBio brings powerful arsenal of information to Amgen

August 03, 2021

Amgen, one of the world’s largest biopharmaceutical companies, announced on July 28 that it will pay $900 million in cash to pick up TeneoBio Inc., a biotechnology firm based in Newark, Calif. Amgen will also make future contingent milestone payments that could be worth up to $1.6 billion in cash. TeneoBio is developing a new class of biologics as therapeutics against cancer, autoimmunity, and infectious diseases. Currently, TeneoBio has a number of products in both pre-clinical and clinical development- these products are for the treatment of multiple myeloma, prostate cancer, and immune disorders. 

What did we learn about the target, TeneoBio, using Foundation?

Its CEO, Roland Buelow, has 45 patents. This bar chart shows his patents by topic and status. Most of his granted patents are in the areas of xenotransplantation and oligopeptides. Most of his patent applications involved oligopeptides, B cell, and organ transplantation.

Roland Buelow's patents by topic and statusRoland Buelow's patents by topic and status

This network graph shows how Buelow’s 36 publications are connected to other authors- including Ben Buelow, another employee of TeneoBio- and various research areas.

TeneoBio's publications by authors and research areas.TeneoBio's publications by authors and research areas.

And there’s even more firepower behind TeneoBio. We looked at the company’s clinical trials, patents, and more.

Clinical trials

On the clinical trials front, TeneoBio has four. Two started in 2019 and two started in 2021. These clinical trials are:

  1. A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma (estimated study completion date is December 2021)
  2. A Study of TNB-486 With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (estimated study completion date is June 2023)
  3. A Study of TNB-585 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma (estimated study completion date is March 2023)
  4. Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma

This table shows where these clinical trials are taking place.

Facilities where TeneoBio clinical trials are taking place.Facilities where TeneoBio clinical trials are taking place.

Patents

TeneoBio has 15 patents. The network graph below shows the tags (research areas) and categories of those patents as well as how they are connected to each other.

Research areas and categories of TeneoBio patents.Research areas and categories of TeneoBio patents.

Grants

The company has also received eight grants. This spline chart shows award amounts- all in the $200,000 range-  and research areas for these grants. Three areas received two grants of $200,000:

  1. Androgen deprivation therapy
  2. Cytokine release syndrome
  3. HBsAG 

resolute-analytics (41)Grants TeneoBio has received by research area.

Publications

TeneoBio has 11 publications. This network graph shows research areas and categories of these publications along with their connections.

TeneoBio publication connections by research area and categories.TeneoBio publication connections by research area and categories.

This stacked area chart shows that TeneoBio began to publish more in 2020 and 2021 (so far) than the previous two years. It also shows the topics on which it published most frequently. Thus far this year, TeneoBio has published most often on biospecific monoclonal antibody and cytokine release syndrome.

TeneoBio publications by research area and date.TeneoBio publications by research area and date.

News

In the past two years, there have been nearly 100 articles written about TeneoBio. In both 2020 and 2021, most of the articles focused on multiple myeloma. 

TeneoBio news by research area and date.TeneoBio news by research area and date.


Research across all of these databases was conducted quickly and efficiently using ResoluteAI’s Foundation. To talk to a real person about how Foundation can help you, please email us at info@resolute.ai or drop us a line using the link below.

Let's talk

Lesley Pink

Lesley Pink, our senior digital editor/writer, has written across a range of industries including artificial intelligence, actuarial science, government, law, and financial journalism. She's a fan of the serial comma and mint chocolate chip ice cream. And no, pink is not her favorite color. You can reach Lesley at lesley@resolute.ai.